As CRS is one of the hallmarks of critically ill COVID-19 patients, it is plausible that administration of immune-suppressive medications such as IL-1 or IL-6 blockade with therapeutic antibodies and antioxidative agents may also mitigate the risk of CSVD in COVID-19 patients. Here, IL6 is linked to COVID-19.